Find information on thousands of medical conditions and prescription drugs.

Irbesartan

Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was discovered by Sanofi Research (now part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade names Aprovel®, Karvea®, and Avapro®. more...

Home

IFEX

Imdur

Imitrex

Imodium

Indahexal

Indapamide

Inderal

Indocin

Indometacin

Infliximab

INH

Inosine

Intal

Invanz

Iressa

Isordil

Isosorbide mononitrate

Isotretinoin

Itraconazole

Ivermectin

Irbesartan is one of the class that patients may be prescribed if they cannot tolerate the ACE-inhibitor drugs, such as perindopril. The usual reason is because of dry cough, attributed to delayed breakdown of bradykinin by ACE. Irbesartan may help to delay the progression of diabetic nephropathy, a form of chronic renal failure due to diabetes.

Irbesartan is also available in a combination formulation with hydrochlorothiazide, marketed as CoAprovel®.

Read more at Wikipedia.org

• [List your site here Free!]


	Application for diabetic nephropathy withdrawn. (Rx: Panel divided on irbesartan).(Brief Article) : An article from: Internal Medicine News $5.95	Irbesartan: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References $32.66

	Angiotensin II Inhibitors Offer Renal Protection.(for people with type 2 diabetes) : An article from: Internal Medicine News $5.95


Do irbesartan and amlodipine reduce cardiovascular events in diabetic patients? - Patient Oriented Evidence That Matters: practice recommendations from Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt ... From Journal of Family Practice, 8/1/03 by Peter S. Millard

Irbesartan-associated persistent edema of the eyelids, face, and neck - Case Reports Abstract Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively ... From Journal of Drugs in Dermatology, 12/1/02 by Philip R. Cohen

Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients ABSTRACT Endothelial dysfunction plays a pivotal role in the development of essential hypertension and its complications. The purpose of this study is ... From British Journal of Biomedical Science, 1/1/03 by Bragulat, E

Prolonged cholestasis associated with irbesartan - Drug Points A 62 year old woman was admitted with a week's history of jaundice. Examination showed deep icterus and hepatomegaly. She had no history of liver disease, ... From British Medical Journal, 9/2/00 by R Hariraj

Cyclosporine After Punctal Plugs A postmenopausal woman with a 5-year history of dry, scratchy burning eyes reported experiencing constant discomfort, despite hourly application of artificial ... From Optometric Management, 11/1/05

Olmesartan for hypertension Synopsis Olmesartan (Benicar) is an angiotensin-II receptor blocker (ARB) labeled for the treatment of hypertension as monotherapy or in combination ... From American Family Physician, 8/15/05 by Kristina E. Ward

For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? EVIDENCE-BASED ANSWER Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are the first-line agents for reducing ... From Journal of Family Practice, 8/1/05 by Santhi Penmetsa

Diabetic nephropathy: common questions Diabetic nephropathy, or diabetic kidney disease, affects 20 to 30 percent of patients with diabetes. It is a common cause of kidney failure. Diabetic ... From American Family Physician, 7/1/05 by Micah L. Thorp

Home

Contact

Resources

Exchange Links

ebay